A clinical-trial flop for Annovis Bio is reminding investors that developing new drugs for Alzheimer's disease is an extremely risky business.
Compare ANVS Stock to Peers
|Symbol||Last Price||Market Cap||% Δ 1 Yr||% Δ 5 Yr|
Annovis Bio, Inc.
News & Analysis: Annovis Bio, Inc.
Treating Alzheimer's is extremely difficult, but these innovative companies are taking a stab at it.
With updates from clinical trials expected as soon as this month, anything is possible.
Find out what pushed them up to see if the good times can keep rolling.